<DOC>
	<DOCNO>NCT02310009</DOCNO>
	<brief_summary>Subjects ( N=48 ) poorly-controlled type 2 diabetes ( HbA1c &gt; 7 % ) assign one 4 follow intervention randomise , parallel group design : [ I ] Control ( placebo injection ; exercise ) , [ II ] Anakinra ( 100 mg subcutaneous injection human recombinant interleukin-1 receptor antagonist ) , [ III ] Exercise ( 1 h cycle ergometry 75 % VO2max ) , [ IV ] Anakinra + Exercise . Pancreatic beta-cell function ( plasma insulin response ) measure intervention use hyperglycemic clamp ( 5.4 mM basal glucose ) combine GLP-1 infusion ( 0.5 pmol/kg/min ) arginine injection ( 5 g bolus ) .</brief_summary>
	<brief_title>IL-1RA , Acute Exercise , Beta-cell Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Type 2 diabetes HbA1c &gt; 7 % HbA1c &gt; 7 % Age &lt; 30 &gt; 80 BMI &lt; 25 &gt; 40 kg/m2 Pregnancy Evidence chronic haematological/renal/hepatic/pulmonary/heart disease &gt; 2kg weight change prior 6 month Alcohol consumption ( men : &gt; 14 drinks/week ; woman : &gt; 7 drinks/week ) Smoking Physical activity &gt; 150 min/week Contraindication exercise Contraindication use anakinra</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Exercise</keyword>
	<keyword>IL-1RA</keyword>
	<keyword>Beta-cell function</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>